GGrantIndex
← Leaderboards

William E. Carson

Ohio State University

Google Scholar ↗PubMed ↗ORCID ↗
$27,905,247
Attributed
$48,179,229
Total exposure
21
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$48,179,229 · 21

By mechanism

UM1$13,818,760 · 1
UG1$7,810,538 · 1
K12$7,773,935 · 1
P01$3,774,800 · 3
R21$3,570,175 · 8
T32$3,410,519 · 1

Top collaborators

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials”

Research focus

Clinical TrialsMalignant NeoplasmsClinical ResearchCancer TherapyTumorProgramsResearch PersonnelUniversitiesOhioTrainingComprehensive Cancer CenterCytokineClinical InvestigatorBasePre-ClinicalCancer PatientDesignResponseImmuneCareerLaboratoriesInvestigational TherapiesPhysiciansSuccess

Grant awards (97)

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network$1,731,705
UM1 · FY2025 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,044,921
UG1 · FY2025 · CA
OSU K12 Training Grant in Oncology$807,955
K12 · FY2025 · CA · contact PI
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers$575,907
R01 · FY2025 · CA
The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network$1,607,030
UM1 · FY2024 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,274,922
UG1 · FY2024 · CA
OSU K12 Training Grant in Oncology$754,562
K12 · FY2024 · CA · contact PI
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers$553,091
R01 · FY2024 · CA
The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network$1,722,607
UM1 · FY2023 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$968,250
UG1 · FY2023 · CA
OSU K12 Training Grant in Oncology$605,618
K12 · FY2023 · CA · contact PI
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers$587,169
R01 · FY2023 · CA
Clinical Protocol and Data Management$466,963
P30 · FY2023 · CA · contact PI
Tumor Immunology$323,426
T32 · FY2023 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,083,717
UG1 · FY2022 · CA
OSU K12 Training Grant in Oncology$810,000
K12 · FY2022 · CA · contact PI
Clinical Protocol and Data Management$466,963
P30 · FY2022 · CA · contact PI
Tumor Immunology$280,752
T32 · FY2022 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,238,889
UG1 · FY2021 · CA
OSU K12 Training Grant in Oncology$797,380
K12 · FY2021 · CA · contact PI
Clinical Protocol and Data Management$466,963
P30 · FY2021 · CA · contact PI
Evaluation of deoxynucleosides as a novel resistance mechanism for radiotherapy$124,999
UM1 · FY2021 · CA · contact PI
The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network$100,000
UM1 · FY2021 · CA · contact PI
Tumor Immunology$40,729
T32 · FY2021 · CA · contact PI
The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network$5,479,018
UM1 · FY2020 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,099,920
UG1 · FY2020 · CA
OSU K12 Training Grant in Oncology$795,680
K12 · FY2020 · CA · contact PI
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment$506,986
U01 · FY2020 · CA
Tumor Immunology$153,487
T32 · FY2020 · CA · contact PI
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$1,541,209
UM1 · FY2019 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,099,919
UG1 · FY2019 · CA
OSU K12 Training Grant in Oncology$809,498
K12 · FY2019 · CA
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment$543,192
U01 · FY2019 · CA
Tumor Immunology$223,276
T32 · FY2019 · CA · contact PI
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$1,512,192
UM1 · FY2018 · CA · contact PI
OSU K12 Training Grant for Clinical Faculty Investigators$793,532
K12 · FY2018 · CA
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment$560,674
U01 · FY2018 · CA
OSU K12 Training Grant for Clinical Faculty Investigators$797,702
K12 · FY2017 · CA
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment$561,330
U01 · FY2017 · CA
Tumor Immunology$261,212
T32 · FY2017 · CA · contact PI
OSU K12 Training Grant for Clinical Faculty Investigators$802,008
K12 · FY2016 · CA
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment$553,079
U01 · FY2016 · CA
MYELOID-DERIVED SUPPRESSOR CELL EFFECTS ON ANTIBODY THERAPY$354,239
P01 · FY2016 · CA · contact PI
Tumor Immunology$187,892
T32 · FY2016 · CA · contact PI
MYELOID-DERIVED SUPPRESSOR CELL EFFECTS ON ANTIBODY THERAPY$354,239
P01 · FY2015 · CA · contact PI
Tumor Immunology$254,018
T32 · FY2015 · CA · contact PI
MYELOID-DERIVED SUPPRESSOR CELL EFFECTS ON ANTIBODY THERAPY$343,613
P01 · FY2014 · CA · contact PI
Tumor Immunology$257,364
T32 · FY2014 · CA · contact PI
MYELOID-DERIVED SUPPRESSOR CELL EFFECTS ON ANTIBODY THERAPY$333,347
P01 · FY2013 · CA · contact PI
Tumor Immunology$243,354
T32 · FY2013 · CA · contact PI
MYELOID-DERIVED SUPPRESSOR CELL EFFECTS ON ANTIBODY THERAPY$355,729
P01 · FY2012 · CA · contact PI
A program of immune-based treatments for cancer$182,272
K24 · FY2012 · CA · contact PI
Tumor Immunology$172,071
T32 · FY2012 · CA · contact PI
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21$400,972
P01 · FY2011 · CA · contact PI
Tumor Immunology$220,410
T32 · FY2011 · CA · contact PI
A program of immune-based treatments for cancer$183,021
K24 · FY2011 · CA · contact PI
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21$414,913
P01 · FY2010 · CA · contact PI
Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors$330,000
R21 · FY2010 · CA
A program of immune-based treatments for cancer$182,273
K24 · FY2010 · CA · contact PI
Tumor Immunology$179,879
T32 · FY2010 · CA · contact PI
Cetuximab Therapy of Pancreatic Cancer: Immune Modulation with IL-21$165,000
R21 · FY2010 · CA · contact PI
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21$408,328
P01 · FY2009 · CA · contact PI
Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors$330,000
R21 · FY2009 · CA
Tumor Immunology$224,780
T32 · FY2009 · CA · contact PI
Cetuximab Therapy of Pancreatic Cancer: Immune Modulation with IL-21$198,000
R21 · FY2009 · CA · contact PI
A program of immune-based treatments for cancer$181,546
K24 · FY2009 · CA · contact PI
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21$417,272
P01 · FY2008 · CA · contact PI
Tumor Immunology$226,779
T32 · FY2008 · CA · contact PI
A program of immune-based treatments for cancer$178,300
K24 · FY2008 · CA · contact PI
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21$392,148
P01 · FY2007 · CA · contact PI
Therapy of Melanoma with Bortezomib and Interferon-alpha$257,668
R21 · FY2007 · CA · contact PI
Therapy of Melanoma with Bortezomib and Interferon-alpha$4,491
R21 · FY2007 · CA · contact PI
Modulation of Tumor CEA Levels for an Anti-CEA Vaccine$288,324
R21 · FY2006 · CA · contact PI
Therapy of Melanoma with Bortezomib and Interferon-alpha$265,363
R21 · FY2006 · CA · contact PI
A Program of Immune-Based Treatments for Cancer$163,858
K24 · FY2006 · CA · contact PI
Tumor Immunology$161,090
T32 · FY2006 · CA · contact PI
Modulation of Tumor CEA Levels for an Anti-CEA Vaccine$295,263
R21 · FY2005 · CA
A Program of Immune-Based Treatments for Cancer$159,241
K24 · FY2005 · CA
PHASE I TRIAL OF INTERLEUKIN-12 IN COMBINATION WITH PACLITAXEL PLUS HERCEPTIN$32,096
M01 · FY2005 · RR
Phase I Trial of IL-12 with Paclitaxel Plus Herceptin$221,736
M01 · FY2004 · RR
A Program of Immune-Based Treatments for Cancer$154,759
K24 · FY2004 · CA
A Program of Immune-Based Treatments for Cancer$150,407
K24 · FY2003 · CA
Phase I Trial of Herceptin Plus IL12$3,348
R21 · FY2003 · CA
Phase 2 Study of Anti Vegf Antibody in Melanoma$265,500
R21 · FY2002 · CA
Phase I Trial of Herceptin Plus IL12$232,115
R21 · FY2002 · CA
Correlative Studies for Phase II Trial of IL12 and IFNa$147,500
R21 · FY2002 · CA
A Program of Immune-Based Treatments for Cancer$146,182
K24 · FY2002 · CA
CORE--CLINICAL CORRELATIVE SCIENCE$0
P01 · FY2002 · CA
Phase 2 Study of Anti Vegf Antibody in Melanoma$264,600
R21 · FY2001 · CA
Phase I Trial of Herceptin Plus IL12$231,525
R21 · FY2001 · CA
PHASE I TRIAL OF INTERLEUKIN 12 FOLLOWED BY INTERFERON$193,916
M01 · FY2001 · RR
Correlative Studies for Phase II Trial of IL12 and IFNa$141,478
R21 · FY2001 · CA
DEVELOPMENT OF NOVEL CORRELATIVE STUDIES FOR A PHASE I$146,000
R21 · FY2000 · CA
PHASE I TRIAL OF INTERLEUKIN 12 FOLLOWED BY INTERFERON$48,578
M01 · FY2000 · RR
DEVELOPMENT OF NOVEL CORRELATIVE STUDIES FOR A PHASE I$2,000
R21 · FY2000 · CA
DEVELOPMENT OF NOVEL CORRELATIVE STUDIES FOR A PHASE I$2,000
R21 · FY2000 · CA
PHASE I TRIAL OF INTERLEUKIN 12 FOLLOWED BY INTERFERON$0
M01 · FY2000 · RR